UVA is working with VDH to trace contacts and assist those exposed, aiming to limit the spread of this potentially ...

Bonner said anyone exhibiting symptoms of the disease should make an appointment with Student Health and Wellness for ...

Meningococcal Vaccine MarketThe global meningococcal vaccine market is experiencing significant growth, driven by rising ...

The story has been updated to correct the FDA approval date to Friday, February 14 On Friday, February 14, the FDA approved ...

The FDA approved GSK’s pentavalent meningococcal vaccine to protect children and young adults aged 10 to 25 years against ...

A mom and dad in England are raising awareness of meningitis — and raising money in their 4-year-old son's honor — after the ...

Penmenvy, which protects against five common types of disease-causing bacteria, is cleared for use in people aged 10 through ...

Thousands of U.S. health agency employees were terminated and told it was for poor performance, though they'd received strong ...

For patients transitioning from rituximab to ravulizumab, meningococcal vaccination can be safely done within 6 months after stopping rituximab.

GSK's Penmenvy wins FDA approval to protect against five meningococcal serogroups. The CDC panel will vote on usage recommendations on Feb. 26.

Background: Given the broad age range across which the quadrivalent meningococcal conjugate vaccine MenACWY-CRM is used, coadministration with routine vaccines should be evaluated across age ...

The US Food and Drug Administration (FDA) approved British drug maker GSK’s combination vaccine to protect against meningococcal infection for use in people aged 10 through 25 years, the company ...